ADJUVANT Randomized Controlled Trial: Rationale and Design
Journal of the American Heart Association · 17.03.2026 · 15 (6)
DOI: 10.1161/jaha.125.045967 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 17.03.2026. Verfasst von Hongfei Sang und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Hangzhou First People's Hospital Westlake University School of Medicine Hangzhou China. Hauptthemen laut MEDLINE: Endovascular Procedures, Fibrinolytic Agents, Ischemic Stroke, Platelet Aggregation Inhibitors. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Intravenous thrombolysis followed by endovascular thrombectomy (EVT) is a first‐line recommended strategy for thrombolysis‐eligible patients with stroke due to acute large‐vessel occlusion. Tirofiban, one of the most used glycoprotein IIb/IIIa receptor inhibitors, has been increasingly advocated to counteract different stages of thrombosis mediated by activated platelets. It is unclear whether tirofiban could be used as an alternative to thrombolysis as adjuvant medicine for EVT. This trial aims to assess whether intravenous tirofiban plus EVT is noninferior to intravenous thrombolysis bridging with EVT in patients with acute ischemic stroke due to large‐vessel occlusion who are eligible for thrombolysis.
Methods
ADJUVANT (Intravenous Tirofiban Versus Thrombolysis Before Endovascular Stroke Thrombectomy) is an investigator‐initiated, multicenter, randomized, open‐label, noninferiority trial with blinded end point assessment conducted at 42 thrombectomy‐capable centers in China. This trial will randomize 976 thrombolysis‐eligible stroke patients with confirmed occlusion of the internal carotid artery, M1/M2 segments of the middle cerebral artery, or basilar artery in a 2:1 ratio to receive intravenous tirofiban plus EVT or intravenous thrombolysis bridging with EVT.
Results
The primary efficacy outcome is functional independence, defined as a score of 0 to 2 on the modified Rankin scale, at 90 days. Safety outcomes are symptomatic intracranial hemorrhage within 48 hours and death within 90 days.
Conclusions
ADJUVANT will provide unique information about the efficacy and safety of adjuvant intravenous tirofiban before EVT in thrombolysis‐eligible patients with stroke due to acute large‐vessel occlusion. Registration URL: https://clinicaltrials.gov . Unique Identifier: NCT05728333.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Affiliated Hangzhou First People's Hospital Westlake University School of Medicine Hangzhou China.
- School of Medicine Zhejiang University Hangzhou China.
- Department of Emergency Xiangtan Central Hospital Xiangtan China.
- Department of Emergency Taihe County People's Hospital Fuyang China.
- Department of Neurology Jingdezhen First People's Hospital Jingdezhen China.
- Department of Neurology Shenqiu County People's Hospital Zhoukou China.
ORCID-Profile: Hongfei Sang, Zhilin Zheng, Heng Ni, Wenqing Xia, Huan Huang, Yongji Zhou, Lin Jiang, Guangxiong Yuan, Shunfu Jiang, Yanling Li, Xianjun Huang, Fei Liu, Caixiu Lin, Lingling Zhang, Bruce C V Campbell, Gregory W Albers, Raul G Nogueira, Thanh N Nguyen, Duolao Wang, Jeffrey L Saver, Qingwu Yang, Zhongming Qiu, Congguo Yin
Zitieren
APA
Sang, H., Zheng, Z., Ni, H., Gu, X., Xia, W., Huang, H., Liu, K., Zhou, Y., Jiang, L., Li, L., Yuan, G., Cui, T., Jiang, S., Li, Y., Jiang, Y., Fang, X., Huang, X., Li, M., Liu, F., …, & ADJUVANT investigators (2026). ADJUVANT Randomized Controlled Trial: Rationale and Design. Journal of the American Heart Association, 15(6). https://doi.org/10.1161/jaha.125.045967
Vancouver
Sang H, Zheng Z, Ni H, Gu X, Xia W, Huang H, et al. ADJUVANT Randomized Controlled Trial: Rationale and Design. Journal of the American Heart Association. 2026;15(6). doi:10.1161/jaha.125.045967
BibTeX
@article{Sang2026,
author = {Sang, Hongfei and Zheng, Zhilin and Ni, Heng and Gu, Xin and Xia, Wenqing and Huang, Huan and Liu, Keqin and Zhou, Yongji and Jiang, Lin and Li, Lingfei and Yuan, Guangxiong and Cui, Tao and Jiang, Shunfu and Li, Yanling and Jiang, Yiqing and Fang, Xing and Huang, Xianjun and Li, Mingchao and Liu, Fei and Lin, Caixiu and Fan, Xuemei and Feng, Danyu and Zhang, Lingling and Campbell, Bruce C V and Albers, Gregory W and Nogueira, Raul G and Nguyen, Thanh N and Wang, Duolao and Saver, Jeffrey L and Yang, Qingwu and Qiu, Zhongming and Yin, Congguo and ADJUVANT investigators, ADJUVANT investigators},
title = {ADJUVANT Randomized Controlled Trial: Rationale and Design},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {6},
doi = {10.1161/jaha.125.045967}
}
EUVIMED